It is escaping me now

specifically which inflammatory markers

have been demonstrably lowered by rvx-208.

I seem to recall reductions in

c-reactive protein

but there were others as well, right?

Did they include

Hla-b27 antigens?

ESRs?

If so.. would there be similar indications

to diabetes and kidney disease, where

cardiac problems develop - such as

patients with auto-immune inflammatory

disorders?

For instance, have been reading that patients with

ankylosing spondylitis tend to have elevated

Hla- b27, and that this in turn can lead to

conduction abnormalities and several other

cardiac problems. (Not sure re: causality vs.

correlation, but I think they have been looking at

pathways. ..so I think it may be a causal relationship.)

If I understand correctly...in addition to CRP,

Elevated hla-b27 is an indicator of more problematic

cardiac outcomes for immune disease patients.

Could rvx-208 help these patients as well?

Or maybe they already listed SLE as another

possible target. Sorry, it ha's been a while

Since 90% of ankylosing sponyliti's patients have

elevated hla-b27, seems like a possible match

for apabetalone (or another similarly designed

compound) ?

Better go re-read those talks.

Just a question. Thanks.